Reseller Ordering

Why Should I Use Revian?

The results are impressive and real.

REVIAN RED is clinically proven to grow more hair in less time than other hair loss products.

Real Results

To test the effectiveness of our dual band LED light therapy, we conducted a double-blind, placebo-controlled study — the “gold standard” of human trials. Enrolling men and women ages 18-65 with pattern baldness (androgenetic alopecia), the study results demonstrate that REVIAN RED is an effective alternative to chemical-based topicals and prescription drugs.

All LED Cap
26.3 hairs/cm2 @ 16 weeks(1)
Red Laser
16.3 hairs/cm2
@ 26 weeks(2)
16.2 hairs/cm2
@ 16 weeks(2)
11.6 hairs/cm2
@ 26 weeks(2)
Net Change in Hair Count

Rogaine® is a registered trademark of Johnson & Johnson Inc.
Propecia® is a registered trademark of MERCK & CO., Inc.

Clinical Efficacy

In the medical community, what do health-care providers consider success?

Hairs grown per centimeter squared is the metric relied upon most and is used in the majority of well controlled hair loss clinical trials.

Continued Growth

Actual REVIAN RED Clinical Trial Participants

Male Patients

Patient ID SCD-023 After 16 Weeks

SCD-023 diagnosed with Norwood-Hamilton classification of III, showing moderate hair loss at the crown.

Patient ID SCD-029 After 16 Weeks

SCD-029 diagnosed with Norwood-Hamilton classification of III, showing moderate hair loss at the midline.

Female Patients

Patient ID PRS-102 After 16 Weeks

PRS-102 diagnosed with Ludwig classification of I-4, showing moderate hair loss at the crown.

Patient ID SCD-113 After 16 Weeks

SCD-113 diagnosed with Ludwig classification of I-4, showing moderate hair loss at the crown.

How Does REVIAN Compare?

vs. Finasteride

First approved as Propecia® in 1997. Prescription oral tablet (1mg) generically available since 2006.

After 16 weeks, subjects treated with REVIAN RED had on average, >80% more total hairs than those treated with once daily finasteride for 26 weeks.*

Finasteride Negatives:
Systemic therapy, requires doctor visit, potential side effects include lower sex drive and erectile dysfunction.

vs. Minoxidil

First approved as Rogaine® in 1988. Over-the-counter topical with both 2% & 5% generically available since 2003.

After 16 weeks, subjects treated with REVIAN RED had on average, 30% more total hairs than those treated with twice daily 5% minoxidil foam.*

Minoxidil Negatives:
2x Daily, goopy/messy chemical treatment, potential side effects include skin rash and irritation.


vs. Laser Device

First Low-Level Laser Therapy (LLLT) device cleared for the treatment for androgenetic alopecia in 2007.

Compared to a red laser device, REVIAN RED provides a more uniform LED scalp coverage with greater hair counts in significantly less time.*

Laser Device Negatives:
Uneven light distribution – bulky, corded or handheld devices that limit ease of use and mobility.


No head-to-head trials were conducted. Percentages derived from cross study comparisons to published results for net change in hair counts vs. placebo/control arm.

How Does REVIAN Work?

The REVIAN RED System is built around a wearable, completely wireless ‘smart’ cap that is controlled by a mobile app.

The rechargeable battery operated cap reverses hair loss in men and women via the first and only, dual band all LED light therapy.

This patented combination of two wavelengths of LED light generate nitric oxide to promote scalp healing and renew the cells that grow hair.

How it Works

REV-01 Clinical Trial Results

Participants who were treated with the red light therapy and were at least 80% compliant for the duration of the study (n=18) had an average of 26.3 more hairs per cm² compared to those who wore a similar cap but did not have light therapy after 16 weeks (n=18).

Subjects treated with placebo continued to lose hair over the duration of the study given the severity of pattern hair loss enrolled into the study (men with Norwood-Hamilton classifications of IIa – V and women with Ludwig-Savin Scale I-1 to I-4, II -1, II-2 or frontal patterns of hair loss).

Placebo Cap


Primary Endpoint: Target Area Hair Counts at Week 16
Mean results shown for the Efficacy Evaluable Population of trial participants who completed all 16 weeks, had no major protocol violations, and who were at least 80% compliant with the treatment regimen for the duration of the trial.

For full trial information, see : NCT04019795

Compliance Made Simple

For any hair growth regimen to work, compliance is key. Failure to use the product is almost certain to lead to a failure in new hair growth. The REVIAN RED app tracks your daily progress while providing a direct link to our team so that we are with you every step of the way.

In fact, participants in the REVIAN RED clinical trial, that had at least 80% compliance to the once daily, 10-minute treatment regimen grew more hair on average than the broad study population.


Greater Compliance Equals Greater Results


Hair Growth System

$995 + Free Shipping

The REVIAN RED System for hair regrowth is an innovative hair growth system, available to both men and women.

Our money back guarantee gives you peace of mind that you can try our product for six months and if you don’t see results, we will take it back. What have you got to lose—besides more hair?

0$ down, 0% APR financing available at checkout.

Buy Now


  1. REV-01 Data on File. A multicenter, double-blind, placebo controlled study was conducted enrolling both men and women ages 18 and older with androgenetic alopecia. Participants were randomized to wear either the REVIAN RED cap or a Placebo Cap (no red light) for 10 minutes per day. Approximately half of the subjects had treatment with REVIAN RED light therapy; and half did not. Total hair counts were obtained from computer assisted scans of digital photographs taken of a defined target area (1 cm 2) centered around a tattoo located in the anterior mid area of the scalp. Identifier: NCT04019795.
  2. Jimenez et al. Efficacy and Safety of a Low-level Laser Device in the Treatment of Male and Female Pattern Hair Loss: A Multicenter, Randomized, Sham Device-controlled, Double-blind Study. American Journal of Clinical Dermatology 2014. PubMed Reference.
  3. Olsen et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versusplacebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology 2007. PubMed Reference.
  4. Leyden et al. Finasteride in the treatment of men with frontal male pattern hair loss. Journal of the American Academy of Dermatology 1999. PubMed Reference.